Matches in SemOpenAlex for { <https://semopenalex.org/work/W1967402398> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W1967402398 endingPage "6SCA" @default.
- W1967402398 startingPage "6SCA" @default.
- W1967402398 abstract "Introduction. Advances in perfluorocarbon (PFC) technology have led to the development of improved 2nd generation O2 carriers such as perflubron emulsion.* Because perflubron emulsion has a high solubility coefficient for O2 and CO (2) and effectively releases O2 to tissue, its therapeutic application as a neuroprotectant during cardiopulmonary bypass (CPB) is being investigated. *(AFO 144; Alliance Pharmaceutical Corporation, San Diego, California) Methods. Following IRB approval and informed consent, 35 CABG patients were studied in 3 treatment groups: 1) Control (Normosol, 3 ml/kg, n = 10); 2) Low-Dose Perflubron (LDP, 3 ml/kg = 1.8 g/kg, n = 13); 3) High-Dose Perflubron (HDP, 2.7 g/kg, n = 12). At start of CPB, all groups underwent normovolemic hemodilution (2 units whole blood removed). Cerebral Blood Flow (CBF) was determined using133 Xe clearance (Initial slope index) at four time periods: 1) 5 mins. post start of CPB; 2) 10 mins. following administration of Normosol or Perflubron; 3) 10 mins. after cooling to 32[degree sign]C; 4) after rewarming to 36[degree sign]C. After an overall repeated measures test, ANOVA testing of group differences at each time period were done, adjusting for the effects of Hct & PaCO2, on CBF. Significance level was set at alpha = 0.05. Results. Baseline values for CBF, Hct, PaCO2, BP and temp. were similar in all groups. A significant overall perflubron emulsion effect on CBF was found (p = 0.0247). At time period 2, CBF increased 28.8% and 18.2% in the LDP and HDP group respectively, compared to 3.8% in the Control Group. CBF was significantly higher in the LDP Group than in the Control Group at all three time periods after administration. In the HDP group, CBF was higher than in the Control Group at periods 3 & 4. Discussion. In other studies, PFC-induced increases in CBF, especially to cortical gray matter, has been reported. [1,2] This is the first preliminary report of increased CBF in humans, resulting from a PFC administered during CPB. Since other influences on CBF (Hct, PaCO2, BP, temp.) have been controlled, we hypothesize that perflubron emulsion may have a local vasodilatory effect on cerebral vasculature. (Figure 1)Figure 1" @default.
- W1967402398 created "2016-06-24" @default.
- W1967402398 creator A5004402213 @default.
- W1967402398 creator A5009563886 @default.
- W1967402398 creator A5011966880 @default.
- W1967402398 creator A5026742752 @default.
- W1967402398 creator A5034645400 @default.
- W1967402398 creator A5036572559 @default.
- W1967402398 creator A5040015835 @default.
- W1967402398 creator A5071203793 @default.
- W1967402398 creator A5084014071 @default.
- W1967402398 date "1998-04-01" @default.
- W1967402398 modified "2023-09-23" @default.
- W1967402398 title "PERFLUBRON EMULSION ADMINISTRATION DURING CARDIOPULMONARY BYPASS-PRELIMINARY RESULTS OF INCREASED CEREBRAL BLOOD FLOW" @default.
- W1967402398 doi "https://doi.org/10.1097/00000539-199804001-00006" @default.
- W1967402398 hasPublicationYear "1998" @default.
- W1967402398 type Work @default.
- W1967402398 sameAs 1967402398 @default.
- W1967402398 citedByCount "1" @default.
- W1967402398 crossrefType "journal-article" @default.
- W1967402398 hasAuthorship W1967402398A5004402213 @default.
- W1967402398 hasAuthorship W1967402398A5009563886 @default.
- W1967402398 hasAuthorship W1967402398A5011966880 @default.
- W1967402398 hasAuthorship W1967402398A5026742752 @default.
- W1967402398 hasAuthorship W1967402398A5034645400 @default.
- W1967402398 hasAuthorship W1967402398A5036572559 @default.
- W1967402398 hasAuthorship W1967402398A5040015835 @default.
- W1967402398 hasAuthorship W1967402398A5071203793 @default.
- W1967402398 hasAuthorship W1967402398A5084014071 @default.
- W1967402398 hasBestOaLocation W19674023981 @default.
- W1967402398 hasConcept C126322002 @default.
- W1967402398 hasConcept C127413603 @default.
- W1967402398 hasConcept C157767197 @default.
- W1967402398 hasConcept C158846371 @default.
- W1967402398 hasConcept C2778123984 @default.
- W1967402398 hasConcept C2778881276 @default.
- W1967402398 hasConcept C42219234 @default.
- W1967402398 hasConcept C42360764 @default.
- W1967402398 hasConcept C71924100 @default.
- W1967402398 hasConceptScore W1967402398C126322002 @default.
- W1967402398 hasConceptScore W1967402398C127413603 @default.
- W1967402398 hasConceptScore W1967402398C157767197 @default.
- W1967402398 hasConceptScore W1967402398C158846371 @default.
- W1967402398 hasConceptScore W1967402398C2778123984 @default.
- W1967402398 hasConceptScore W1967402398C2778881276 @default.
- W1967402398 hasConceptScore W1967402398C42219234 @default.
- W1967402398 hasConceptScore W1967402398C42360764 @default.
- W1967402398 hasConceptScore W1967402398C71924100 @default.
- W1967402398 hasIssue "Supplement" @default.
- W1967402398 hasLocation W19674023981 @default.
- W1967402398 hasOpenAccess W1967402398 @default.
- W1967402398 hasPrimaryLocation W19674023981 @default.
- W1967402398 hasRelatedWork W1991604659 @default.
- W1967402398 hasRelatedWork W2034523422 @default.
- W1967402398 hasRelatedWork W2052863171 @default.
- W1967402398 hasRelatedWork W206795022 @default.
- W1967402398 hasRelatedWork W2069314424 @default.
- W1967402398 hasRelatedWork W2462746312 @default.
- W1967402398 hasRelatedWork W2538808612 @default.
- W1967402398 hasRelatedWork W3129089517 @default.
- W1967402398 hasRelatedWork W4253140277 @default.
- W1967402398 hasRelatedWork W2074942032 @default.
- W1967402398 hasVolume "86" @default.
- W1967402398 isParatext "false" @default.
- W1967402398 isRetracted "false" @default.
- W1967402398 magId "1967402398" @default.
- W1967402398 workType "article" @default.